<DOC>
	<DOCNO>NCT02119650</DOCNO>
	<brief_summary>The purpose study determine ruxolitinib , combination Pemetrexed/Cisplatin Pemetrexed Maintenance , safe effective treatment nonsquamous non-small cell lung cancer ( NSCLC ) Stage IIIB , Stage IV , recurrent .</brief_summary>
	<brief_title>Ruxolitinib Combination With Pemetrexed/Cisplatin Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The study consist open-label , safety run-in ( consist 1 4 cohort 9 subject ) , confirm safety ruxolitinib combination pemetrexed/cisplatin subject nonsquamous non-small cell lung cancer ( NSCLC ) Stage IIIB , Stage IV , recurrent . Subjects safety run-in receive open-label ruxolitinib pemetrexed cisplatin . In second part study , subject enrol randomized receive pemetrexed cisplatin ( open-label ) either ruxolitinib placebo blind manner . The dose ruxolitinib administer determine data produce safety run-in phase . Treatment consist repeat 21-day cycle . Subjects receive infusion pemetrexed cisplatin Day 1 cycle ruxolitinib/placebo self-administered entire cycle . Maintenance therapy ruxolitinib placebo combination pemetrexed , base original treatment assignment , allow subject eligible maintenance therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis nonsquamous NSCLC Stage IIIB Stage IV , recurrent prior definitive intervention ( radiation , surgery , chemoradiation therapy , without adjuvant neoadjuvant chemotherapy ) . Radiographically measurable evaluable disease . Life expectancy least 12 week . Tumor without activate driver mutation available therapy ( eg , tumor without mutation epidermal growth factor receptor anaplastic lymphoma ) . An mGPS 1 2 define : *Criteria : Creactive protein &gt; 10 mg/L AND albumin â‰¥35 g/L ; Score = 1 Creactive protein &gt; 10 mg L AND albumin &lt; 35 g/L ; Score = 2 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate renal , hepatic , bone marrow function demonstrate protocolspecified laboratory parameter screen visit . Squamous mixed histology ( eg , adenosquamous ) NSCLC Previous systemic therapy advance metastatic disease . Known active central nervous system ( CNS ) metastases . Current previous malignancy within 2 year study entry , except cure basal squamous cell skin cancer , superficial bladder cancer , prostate intraepithelial neoplasm , carcinoma situ cervix , noninvasive indolent malignancy without sponsor approval . Current uncontrolled cardiac disease angina myocardial infarction , congestive heart failure include New York Heart Association functional classification 3 , arrhythmia require treatment . Uncontrolled concomitant medical condition , include , limited , renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , neurological , cerebral , psychiatric disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Non small cell lung cancer</keyword>
</DOC>